# Jason J. Luke

Source: https://onco.cc/people/jason-luke/  
OnCo record `jason-luke` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma.

## Summary

Jason Luke was principal investigator of KEYNOTE-716, which showed adjuvant pembrolizumab reduces recurrence and distant metastasis in resected stage IIB and IIC melanoma, the first adjuvant immunotherapy approval in stage II disease. He runs one of the largest early-phase immunotherapy programmes in the United States and studies mechanisms of primary resistance to checkpoint blockade. He is active in SITC leadership.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: melanoma; adjuvant; early-phase
- Role: Director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center
- Specialisms: Melanoma; Adjuvant immunotherapy; Early-phase immunotherapy; Immune resistance

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Luke%20JJ%5BAuthor%5D%20melanoma%20pembrolizumab

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Stage IIB and IIC melanoma](https://onco.cc/cancers/stage-ii-melanoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Society for Immunotherapy of Cancer](https://onco.cc/institutions/sitc/), [UPMC Hillman Cancer Center](https://onco.cc/institutions/upmc-hillman/)
- trials: [KEYNOTE-716](https://onco.cc/trials/keynote-716/)
- journals: [Nature Reviews Clinical Oncology](https://onco.cc/journals/nature-reviews-clinical-oncology/)

---
JSON: https://onco.cc/api/v1/entities/jason-luke.json